Health Plan News logo

Fake Prescriptions Still an Issue; Corey Haim Death Highlights Problem

With the recent untimely death of actor Cory Haim this week, the public is learning about an industry-wide problem that continues to plague the health insurance industry, fake prescriptions.

Corey Ian Haim (December 23, 1971 – March 10, 2010) was a Canadian actor, best for his 1980s Hollywood career as a teen idol. Mr. Haim starred or co-starred in a number of movies like Lucas, Murphy’s Romance, The Lost Boys, License to Drive, and Dream a Little Dream. Corey Haim appeard many times alongside his friend Corey Feldman. The two later starred in the hit A&E reality television show called The Two Coreys.

Corey Haim died an untimely death on March 10, 2010.

According to the Examiner, “A state investigation turned up an unauthorized prescription in Corey Haim’s name. According to People.com, the illegal prescription was noticed when investigators ordered drug pads from a San Diego vendor. The prescriptions were filled out by using the stolen identity of doctors. Authorities have described this prescription drug ring as “massive”.

California Attorney General Jerry Brown said that the illegal prescription made out to Corey Haim was for the pain killer OxyContin. The prescription was located through the California computer database that tracks all prescriptions that are filled in the state.”

The Associated Press is also reporting that “California Attorney General Jerry Brown said records of the prescription in the name of the former teen heartthrob were found during an investigation of the ring that illegally obtained prescription pads and used the stolen identities of doctors to fill them out.”

The public is learning of the problem of fake drug prescriptions because of this celebrity’s untimely death and the fact that one of the prescriptions that was part of illegally obtained prescription pads and the stolen identities of physicians. There continues to be calls for changes in the way prescriptions are written that will make it more difficult for fake prescriptions to be obtained by the public.

March 11th 2010
Tags: Healthcare Plan News

Comments Off

Blue Cross Blue Shield of Michigan Foundation Wins Big at 2010 Wilmer Shields Rich Awards Program

The Blue Cross Blue Shield of Michigan Foundation earned two national awards for Excellence in Communications, one gold and one silver, in the 2010 Wilmer Shields Rich Awards Program. The awards, given by the Council on Foundations and the Communications Network, recognize important communication efforts that increase public awareness of ...
March 2nd 2010
Tags: Healthcare Plan News

Comments Off

HealthPass Now Offering UnitedHealthcare’s Oxford Health Benefit Plans

HealthPass, a partnership between New York City, the New York Business Group on Health, and the health insurance industry, is now offering five of UnitedHealthcare's Oxford health insurance plans to employers. To qualify, the employers must have two to 50 eligible employees and be based in New York City or ...
March 2nd 2010
Tags: Healthcare Plan News

Comments Off

Verizon Wireless’ Mobile Healthcare Solutions Let Hospitals and Clinics Streamline Communications and Access Critical Data

BASKING RIDGE, N.J., and ATLANTA, March 2 /PRNewswire/ -- Healthcare organizations ranging from large city hospitals to rural community health clinics can count on Verizon Wireless to deliver customized wireless solutions that allow caregivers the ability to utilize resources that enhance the patient experience. Representatives from Verizon Wireless, operator of ...
March 2nd 2010
Tags: Healthcare Plan News

Comments Off

Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing. "Our NS5A inhibitor program ...
March 2nd 2010
Tags: Healthcare Plan News

Comments Off

Abbott and Enanta Announce Advancement of Hepatitis C Collaboration

ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and ...

Search

The archives run deep. Feel free to search older content using topic keywords.

Browse by Category